SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF BREAST CANCER WITH POSITIVE HORMONAL RECEPTORS AND NEGATIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2. (submitted in 2019)